New liquid biopsy could replace needle biopsies for prostate cancer
NCT ID NCT05141383
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study collected urine and blood samples from 80 men, including those with prostate cancer, suspected cancer, or benign prostate enlargement, as well as healthy donors. The goal was to find RNA biomarkers that could lead to a simple liquid biopsy test for diagnosing and monitoring prostate cancer. Researchers are analyzing the samples to see if they can reliably detect cancer without invasive procedures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could lead to a simple urine or blood test to diagnose prostate cancer and monitor it without invasive biopsies.
- What could go wrong
- This is an early-stage study focused on collecting samples and developing methods, not yet testing a finished test. The biomarkers may not prove accurate enough in larger, diverse populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY DONORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Curie
Paris, 75005, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?